Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) — Net Asset Quality Index
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has a Net Asset Quality Index of 65.8% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.80 Billion minus total liabilities of CN¥1.30 Billion yields net assets of CN¥2.50 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See how many days can Hangzhou Bio-Sincerity Pharma-Tech Co.Lt fund operations to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Net Asset Quality Index Over Time (2019–2025)
This chart shows how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s Net Asset Quality Index has evolved across 7 annual periods from 2019 to 2025. As of March 2026, the index stands at 65.8%, representing net assets of CN¥2.50 Billion against total assets of CN¥3.80 Billion CNY. Explore Hangzhou Bio-Sincerity Pharma-Tech Co.Lt operating cash flow efficiency to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2019–2025)
The table below presents the year-by-year Net Asset Quality Index for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. from 2019 to 2025, covering 7 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Hangzhou Bio-Sincerity Pharma-Tech Co.Lt stock valuation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 67.5% | CN¥2.49 Billion | CN¥3.69 Billion | CN¥1.20 Billion | ▼ -1.8 pp |
| 2024 | 69.3% | CN¥2.58 Billion | CN¥3.72 Billion | CN¥1.14 Billion | ▼ -3.8 pp |
| 2023 | 73.2% | CN¥2.68 Billion | CN¥3.67 Billion | CN¥984.97 Million | ▼ -11.6 pp |
| 2022 | 84.7% | CN¥2.48 Billion | CN¥2.93 Billion | CN¥447.45 Million | ▲ +5.5 pp |
| 2021 | 79.2% | CN¥2.32 Billion | CN¥2.92 Billion | CN¥607.10 Million | ▲ +27.7 pp |
| 2020 | 51.5% | CN¥339.54 Million | CN¥658.75 Million | CN¥319.20 Million | ▼ -22.1 pp |
| 2019 | 73.6% | CN¥278.74 Million | CN¥378.63 Million | CN¥99.89 Million | — |